Alpha 2.0
Login Register
» Authors » T Lauritzen

T Lauritzen

Explore the profile of T Lauritzen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 133
Citations 1909
Followers 0
Related Specialties
Endocrinology
General Medicine
Public Health
Top 10 Co-Authors
A Sandbaek
K Borch-Johnsen
J S Christiansen
C Binder
T Hansen
J F Lassen
T Deckert
O Pedersen
H T Sorensen
S Pramming
Published In
Diabetologia
Diabet Med
Ugeskr Laeger
Scand J Prim Health Care
J Clin Endocrinol Metab
Affiliations
Soon will be listed here.
Recent Articles
11.
Sex-specific effects of naturally occurring variants in the dopamine receptor D2 locus on insulin secretion and type 2 diabetes susceptibility
Guigas B, de Leeuw van Weenen J, van Leeuwen N, Simonis-Bik A, van Haeften T, Nijpels G, et al.
Diabet Med . 2014 Apr; 31(8):1001-8. PMID: 24724616
Aims: Modulation of dopamine receptor D2 (DRD2) activity affects insulin secretion in both rodents and isolated pancreatic β-cells. We hypothesized that single nucleotide polymorphisms in the DRD2/ANKK1 locus may affect...
12.
Effect of a participant-driven health education programme in primary care for people with hyperglycaemia detected by screening: 3-year results from the Ready to Act randomized controlled trial (nested within the ADDITION-Denmark study)
Maindal H, Carlsen A, Lauritzen T, Sandbaek A, Simmons R
Diabet Med . 2014 Mar; 31(8):976-86. PMID: 24646371
Aim: To assess whether a 12-week participant-driven health education programme offered to individuals with screening-detected hyperglycaemia in Danish primary care would lead to improvements in cardiovascular risk factors, health behaviour...
13.
Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screen-detected diabetes? Results from the ADDITION-Europe cluster randomized trial
Black J, Sharp S, Wareham N, Sandbaek A, Rutten G, Lauritzen T, et al.
Diabet Med . 2014 Feb; 31(6):647-56. PMID: 24533664
Aims: Little is known about the long-term effects of intensive multifactorial treatment early in the diabetes disease trajectory. In the absence of long-term data on hard outcomes, we described change...
14.
Circadian variation in the pharmacokinetics of steady state continuous subcutaneous infusion of growth hormone in adult growth hormone deficient patients
Janukonyte J, Parkner T, Lauritzen T, Christiansen J, Laursen T
Growth Horm IGF Res . 2013 Oct; 23(6):256-60. PMID: 24094495
Background: Previous studies in growth hormone (GH)-deficient (GHD) patients have indicated a possible diurnal variation in the pharmacokinetics (PK) of GH after subcutaneous (sc) GH administration. Thus, higher GH levels...
15.
The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body...
Heraclides A, Jensen T, Rasmussen S, Eugen-Olsen J, Haugaard S, Borch-Johnsen K, et al.
Diabetologia . 2013 Apr; 56(7):1542-6. PMID: 23613086
Aims/hypothesis: Recent evidence links the soluble urokinase plasminogen activator receptor (suPAR), a stable biomarker of systemic immune activation, to several chronic diseases, including type 2 diabetes. suPAR is also associated...
16.
Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes
Albrechtsen A, Grarup N, Li Y, Sparso T, Tian G, Cao H, et al.
Diabetologia . 2012 Nov; 56(2):298-310. PMID: 23160641
Aims/hypothesis: Human complex metabolic traits are in part regulated by genetic determinants. Here we applied exome sequencing to identify novel associations of coding polymorphisms at minor allele frequencies (MAFs) >1%...
17.
Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study
Charles M, Fleischer J, Witte D, Ejskjaer N, Borch-Johnsen K, Lauritzen T, et al.
Diabetologia . 2012 Oct; 56(1):101-8. PMID: 23064291
Aims/hypothesis: There is limited evidence on how multifactorial treatment improves outcomes of diabetes when initiated in the lead time between detection by screening and diagnosis in routine clinical practice. Cardiac...
18.
Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial
Simmons R, Sharp S, Sandbaek A, Borch-Johnsen K, Davies M, Khunti K, et al.
Diabet Med . 2012 Jul; 29(11):e409-16. PMID: 22823477
Aims: To describe the total cardiovascular burden (cardiovascular morbidity or mortality, revascularization or non-traumatic amputation) in individuals with screen-detected diabetes in the ADDITION-Europe trial and to quantify the impact of...
19.
The frequent UCP2 -866G>A polymorphism protects against insulin resistance and is associated with obesity: a study of obesity and related metabolic traits among 17 636 Danes
Andersen G, Dalgaard L, Justesen J, Anthonsen S, Nielsen T, Thorner L, et al.
Int J Obes (Lond) . 2012 Feb; 37(2):175-81. PMID: 22349573
Context: Uncoupling protein 2 (UCP2) is involved in regulating ATP synthesis, generation of reactive oxygen species and glucose-stimulated insulin secretion in β-cells. Polymorphisms in UCP2 may be associated with obesity...
20.
Common variation in oxidative phosphorylation genes is not a major cause of insulin resistance or type 2 diabetes
Snogdal L, Wod M, Grarup N, Vestmar M, Sparso T, Jorgensen T, et al.
Diabetologia . 2011 Nov; 55(2):340-8. PMID: 22095239
Aims/hypothesis: There is substantial evidence that mitochondrial dysfunction is linked to insulin resistance and is present in several tissues relevant to the pathogenesis of type 2 diabetes. Here, we examined...